It is interesting to note that the results presented here are more dramatic than other studies which demonstrated that the BRAF inhibitor PLX4720, the precursor derivative of Vemurafenib, only moderately inhibited tumor growth in vivo without inducing tumor regression [45] or preventing relapse [27]. Here, BRAF is linked to neoplasm.